Brodimoprim, a new bacterial dihydrofolate reductase inhibitor: a minireview
- PMID: 7562018
- DOI: 10.1179/joc.1995.7.3.221
Brodimoprim, a new bacterial dihydrofolate reductase inhibitor: a minireview
Abstract
This brief review article synthesizes the principal literature regarding the clinical status of co-trimoxazole compared to monotherapy with one of the two diaminopyrimidines available commercially: trimethoprim or brodimoprim. Both these inhibitors of bacterial dihydrofolate reductase compare favorably to co-trimoxazole as antimicrobial chemotherapy. Brodimoprim is characterized by its advantageous pharmacokinetics in comparison to both co-trimoxazole and trimethoprim.